Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis.
Edo H J SavelkoulPepijn W A ThomasLauranne A A P DerikxNathan den BroederTessa E H RömkensFrank HoentjenPublished in: Inflammatory bowel diseases (2022)
Annual loss of response was 10% for infliximab and 13% for adalimumab, with higher rates during the first year. Annual dose escalation rates were 14% (infliximab) and 21% (adalimumab), with clinical benefit in 72% and 52%, respectively. Uniform definitions are needed to facilitate more robust evaluations.